Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bausch + Lomb Corporation ( (BLCO) ) just unveiled an announcement.
Bausch + Lomb has launched an R&D “Teach-in” webinar series to give investors and stakeholders deeper insights into its differentiated product pipeline unveiled in late 2025. The first session on March 23, 2026, will feature senior R&D and executive leadership discussing glaucoma programs and strategic priorities.
The event will highlight BL1107, a glaucoma drug candidate designed to address vision loss in addition to lowering intraocular pressure, and ELIOS, an implant-free minimally invasive laser-based glaucoma procedure already available in Europe and targeted for a U.S. launch in the second half of 2026. By showcasing these assets in a forum hosted by Wells Fargo with replay access on its investor site, Bausch + Lomb is underscoring its innovation agenda in glaucoma and signaling potential growth opportunities in its pharmaceutical and surgical franchises.
The most recent analyst rating on (BLCO) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
The score is most constrained by weak financial performance—multi-year net losses and negative free cash flow—despite solid revenue growth and a supportive balance sheet in the latest period. Offsetting this, the earnings call was strong with clear 2026 guidance for improved margins and EBITDA growth, and the technical setup is constructive with the stock trending above key moving averages. Valuation is held back by negative earnings and no stated dividend support.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation is a global eye health company that develops and markets contact lenses, prescription ophthalmic drugs, over-the-counter eye care products and surgical devices. With a nearly 200-year history and a focus on innovation, it targets improving standards of care in vision health for patients and consumers worldwide.
Average Trading Volume: 391,869
Technical Sentiment Signal: Buy
Current Market Cap: $6.04B
For an in-depth examination of BLCO stock, go to TipRanks’ Overview page.